Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-20-021645
Filing Date
2020-11-16
Accepted
2020-11-16 15:36:46
Documents
54
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 732033
2 ex31-1.htm EX-31.1 18845
3 ex31-2.htm EX-31.2 18844
4 ex32-1.htm EX-32.1 10510
  Complete submission text file 0001493152-20-021645.txt   3711398

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE ptix-20200930.xml EX-101.INS 600334
6 XBRL SCHEMA FILE ptix-20200930.xsd EX-101.SCH 49549
7 XBRL CALCULATION FILE ptix-20200930_cal.xml EX-101.CAL 45270
8 XBRL DEFINITION FILE ptix-20200930_def.xml EX-101.DEF 189209
9 XBRL LABEL FILE ptix-20200930_lab.xml EX-101.LAB 336212
10 XBRL PRESENTATION FILE ptix-20200930_pre.xml EX-101.PRE 254501
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51353 | Film No.: 201316285
SIC: 7389 Services-Business Services, NEC